1. Australia's pregabalin use and overdoses have fallen since 2018, BMJ finds
Australia managed something the UK hasn't. Pregabalin overdoses here are heading down, with poison centre calls 47% below where the old trend line said they'd be.
The BMJ study tracked dispensing claims and poison centre data from 2016 to 2024: 3,441,851 scripts to 227,864 people, plus 4,871 overdose calls. Use and overdose both peaked in 2018, then dispensing dropped at three points. The first was December 2018, after the media coverage of harms. The second was May 2020, a month after tighter prescribing restrictions. The third was December 2021, following the February 2021 boxed warnings and the rollout of real-time prescription monitoring.
By December 2021, dispensing was 25% below the projected trend, roughly 118,390 fewer scripts that month, and it was still falling 0.7% a month. Overdose calls were sliding 1.6% a month. Compare the UK, where a gabapentinoid shows up in one-third of substance use deaths and those deaths more than doubled between 2018 and 2022.
The authors are upfront that this is observational, so it shows the timing lined up rather than proving cause. They only counted subsidised scripts, and they couldn't see whether patients lost access to pain treatment or switched to opioids. They also say dispensing still far outstrips what approved indications alone would justify.
In the linked editorial, Professor David Juurlink says pregabalin should be reserved for proven conditions like diabetic nerve pain and fibromyalgia, and avoided for low back pain and sciatica. "Persisting with ineffective treatment or escalating the dose in pursuit of relief that has yet to materialize is more than misplaced optimism. It is an invitation to harm," he writes.
The takeaway: Next time a patient on pregabalin for back pain or sciatica asks "do I still need these tablets?", treat it as an invitation to review rather than a quick renewal. If there's no meaningful benefit, that's your answer.